{
  "doc_id": "3",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "成人2型糖尿病胰岛素临床应用的中国专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "成人2型糖尿病胰岛素临床应用的中国专家共识",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T1",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T2",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T2",
              "tail_entity_id": "T0"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "1",
      "paragraph": "糖尿病已成为严重威胁国人健康的最重要的慢性非传染性疾病之一，但糖尿病控制状况在我国并不容乐观，甚至按纵向比较，血糖控制情况亦无显著改善。2011年公布现状调查显示口服药联合胰岛素治疗的患者中85%HbA1c控制未达标(≥7.o%)糖尿病相关治疗费用中约80%用于糖尿病并发症的治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病已成为严重威胁国人健康的最重要的慢性非传染性疾病之一，但糖尿病控制状况在我国并不容乐观，甚至按纵向比较，血糖控制情况亦无显著改善。2011年公布现状调查显示口服药联合胰岛素治疗的患者中85%HbA1c控制未达标(≥7.o%)糖尿病相关治疗费用中约80%用于糖尿病并发症的治疗。",
          "start_idx": 0,
          "end_idx": 141,
          "entities": [
            {
              "entity_id": "T3",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T4",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 34
            },
            {
              "entity_id": "T5",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 57
            },
            {
              "entity_id": "T6",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 81,
              "end_idx": 83
            },
            {
              "entity_id": "T7",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 89
            },
            {
              "entity_id": "T8",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 103
            },
            {
              "entity_id": "T9",
              "entity": "控制未达标(≥7.o%)",
              "entity_type": "Test_Value",
              "start_idx": 103,
              "end_idx": 115
            },
            {
              "entity_id": "T10",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 118
            },
            {
              "entity_id": "T11",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 134
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R2",
              "head_entity_id": "T5",
              "tail_entity_id": "T4"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R3",
              "head_entity_id": "T7",
              "tail_entity_id": "T10"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R4",
              "head_entity_id": "T8",
              "tail_entity_id": "T10"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "2",
      "paragraph": "众所周知，2型糖尿病患者胰岛β细胞功能随病程进展逐渐恶化。由此推论，随病程进展，为取得血糖最佳控制，大部分2型糖尿病患者似乎最终均需胰岛素治疗。然而，由于社会、经济和心理因素，胰岛素使用不足和使用过度的情况在我国同时并存。因此，规范胰岛素治疗对于改善糖尿病管理、提高广大医护人员的临床实践水平具有重要意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "众所周知，2型糖尿病患者胰岛β细胞功能随病程进展逐渐恶化。由此推论，随病程进展，为取得血糖最佳控制，大部分2型糖尿病患者似乎最终均需胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T12",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T13",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 5,
              "end_idx": 7
            },
            {
              "entity_id": "T14",
              "entity": "胰岛β细胞功能随病程进展逐渐恶化",
              "entity_type": "Pathogenesis",
              "start_idx": 12,
              "end_idx": 28
            },
            {
              "entity_id": "T15",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 45
            },
            {
              "entity_id": "T16",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 58
            },
            {
              "entity_id": "T17",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 53,
              "end_idx": 55
            },
            {
              "entity_id": "T18",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 69
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R5",
              "head_entity_id": "T13",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R6",
              "head_entity_id": "T14",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R7",
              "head_entity_id": "T15",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R8",
              "head_entity_id": "T17",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R9",
              "head_entity_id": "T18",
              "tail_entity_id": "T16"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "然而，由于社会、经济和心理因素，胰岛素使用不足和使用过度的情况在我国同时并存。",
          "start_idx": 72,
          "end_idx": 111,
          "entities": [
            {
              "entity_id": "T19",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "因此，规范胰岛素治疗对于改善糖尿病管理、提高广大医护人员的临床实践水平具有重要意义。",
          "start_idx": 111,
          "end_idx": 153,
          "entities": [
            {
              "entity_id": "T20",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8
            },
            {
              "entity_id": "T21",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R10",
              "head_entity_id": "T20",
              "tail_entity_id": "T21"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "3",
      "paragraph": "目前临床应用的胰岛素包括动物胰岛素、人胰岛素及胰岛素类似物。其中，人胰岛素具有免疫原性低、长期使用安全可靠、效价比高等优点，在临床中应用最为广泛，在2型糖尿病血糖管理中作用突出。胰岛素类似物通过改变人胰岛素结构从而改变其药代动力学特性，可分为超短效胰岛素类似物和长效胰岛素类似物。因起效和持续时间不同，胰岛素类似物有其各自的特点，但其使用和剂量调整原则与人胰岛素基本相同（表1）。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前临床应用的胰岛素包括动物胰岛素、人胰岛素及胰岛素类似物。其中，人胰岛素具有免疫原性低、长期使用安全可靠、效价比高等优点，在临床中应用最为广泛，在2型糖尿病血糖管理中作用突出。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T23",
              "entity": "动物胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17
            },
            {
              "entity_id": "T24",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T25",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 29
            },
            {
              "entity_id": "T26",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37
            },
            {
              "entity_id": "T27",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 79
            },
            {
              "entity_id": "T28",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 74,
              "end_idx": 76
            },
            {
              "entity_id": "T29",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 79,
              "end_idx": 81
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T28",
              "tail_entity_id": "T27"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T29",
              "tail_entity_id": "T27"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "胰岛素类似物通过改变人胰岛素结构从而改变其药代动力学特性，可分为超短效胰岛素类似物和长效胰岛素类似物。",
          "start_idx": 89,
          "end_idx": 140,
          "entities": [
            {
              "entity_id": "T30",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6
            },
            {
              "entity_id": "T31",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T32",
              "entity": "超短效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 41
            },
            {
              "entity_id": "T33",
              "entity": "长效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 50
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "因起效和持续时间不同，胰岛素类似物有其各自的特点，但其使用和剂量调整原则与人胰岛素基本相同（表1）。",
          "start_idx": 140,
          "end_idx": 190,
          "entities": [
            {
              "entity_id": "T34",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 17
            },
            {
              "entity_id": "T35",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "4",
      "paragraph": "一、合理选择胰岛素治疗时机",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、合理选择胰岛素治疗时机",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "5",
      "paragraph": "对于2型糖尿病患者而言，尽早启动胰岛素治疗能减轻胰岛β细胞的负荷，尽快纠正高血糖状态，迅速解除高糖毒性，改善胰岛素抵抗，保护甚至逆转残存β细胞功能。对于胰岛素起始治疗的时机，不同学术组织的推荐有所不同(表2)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于2型糖尿病患者而言，尽早启动胰岛素治疗能减轻胰岛β细胞的负荷，尽快纠正高血糖状态，迅速解除高糖毒性，改善胰岛素抵抗，保护甚至逆转残存β细胞功能。",
          "start_idx": 0,
          "end_idx": 74,
          "entities": [
            {
              "entity_id": "T37",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T38",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T39",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19
            },
            {
              "entity_id": "T40",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 40
            },
            {
              "entity_id": "T41",
              "entity": "高糖毒性",
              "entity_type": "Pathogenesis",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T42",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 54,
              "end_idx": 59
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R13",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T39",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R15",
              "head_entity_id": "T41",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R16",
              "head_entity_id": "T42",
              "tail_entity_id": "T37"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "对于胰岛素起始治疗的时机，不同学术组织的推荐有所不同(表2)。",
          "start_idx": 74,
          "end_idx": 105,
          "entities": [
            {
              "entity_id": "T43",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 5
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "6",
      "paragraph": "多项研究表明，亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低，糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著。因此，中国2型糖尿病患者应适时启动胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "多项研究表明，亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低，糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著。因此，中国2型糖尿病患者应适时启动胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 80,
          "entities": [
            {
              "entity_id": "T44",
              "entity": "亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低",
              "entity_type": "Pathogenesis",
              "start_idx": 7,
              "end_idx": 32
            },
            {
              "entity_id": "T45",
              "entity": "糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著",
              "entity_type": "Pathogenesis",
              "start_idx": 33,
              "end_idx": 56
            },
            {
              "entity_id": "T46",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67
            },
            {
              "entity_id": "T47",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64
            },
            {
              "entity_id": "T48",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 77
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R17",
              "head_entity_id": "T47",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R18",
              "head_entity_id": "T48",
              "tail_entity_id": "T46"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "7",
      "paragraph": "本共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全；(4)妊娠期间。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "本共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全；(4)妊娠期间。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T49",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T50",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10
            },
            {
              "entity_id": "T51",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T52",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 80
            },
            {
              "entity_id": "T53",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 74,
              "end_idx": 75
            },
            {
              "entity_id": "T54",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 75,
              "end_idx": 76
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R19",
              "head_entity_id": "T50",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R20",
              "head_entity_id": "T51",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R21",
              "head_entity_id": "T53",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T54",
              "tail_entity_id": "T52"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "8",
      "paragraph": "以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，HbA1c≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药物次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)的患者；(3)病程中出现无明显诱因的体重下降者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，HbA1c≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药物次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)的患者；(3)病程中出现无明显诱因的体重下降者。",
          "start_idx": 0,
          "end_idx": 145,
          "entities": [
            {
              "entity_id": "T55",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T56",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 19,
              "end_idx": 21
            },
            {
              "entity_id": "T57",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T58",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 42
            },
            {
              "entity_id": "T59",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39
            },
            {
              "entity_id": "T60",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 50
            },
            {
              "entity_id": "T61",
              "entity": "≥9.0%",
              "entity_type": "Test_Value",
              "start_idx": 50,
              "end_idx": 55
            },
            {
              "entity_id": "T62",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 59
            },
            {
              "entity_id": "T63",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 73,
              "end_idx": 79
            },
            {
              "entity_id": "T64",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 87,
              "end_idx": 89
            },
            {
              "entity_id": "T65",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 103,
              "end_idx": 105
            },
            {
              "entity_id": "T66",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 106,
              "end_idx": 109
            },
            {
              "entity_id": "T67",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 115
            },
            {
              "entity_id": "T68",
              "entity": "≥7.0%",
              "entity_type": "Test_Value",
              "start_idx": 115,
              "end_idx": 120
            },
            {
              "entity_id": "T69",
              "entity": "体重下降",
              "entity_type": "Symptom",
              "start_idx": 139,
              "end_idx": 143
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R23",
              "head_entity_id": "T59",
              "tail_entity_id": "T58"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R24",
              "head_entity_id": "T60",
              "tail_entity_id": "T58"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "9",
      "paragraph": "二、初始胰岛素治疗方案的制定",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、初始胰岛素治疗方案的制定",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T70",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "10",
      "paragraph": "临床医师在制定胰岛素方案、剂量调整和设定糖尿病血糖控制目标时，除考虑病理生理因素外，还必须考虑社会经济因素，并统筹考虑安全性、可行性和科学性，制定个体化的血糖控制目标和起始治疗方案。同时，在治疗过程中，应及时进行临床评价，进行适当调整。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床医师在制定胰岛素方案、剂量调整和设定糖尿病血糖控制目标时，除考虑病理生理因素外，还必须考虑社会经济因素，并统筹考虑安全性、可行性和科学性，制定个体化的血糖控制目标和起始治疗方案。",
          "start_idx": 0,
          "end_idx": 91,
          "entities": [
            {
              "entity_id": "T71",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T72",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T73",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25
            },
            {
              "entity_id": "T74",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 79
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T71",
              "tail_entity_id": "T72"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R26",
              "head_entity_id": "T73",
              "tail_entity_id": "T72"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "同时，在治疗过程中，应及时进行临床评价，进行适当调整。",
          "start_idx": 91,
          "end_idx": 118,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "11",
      "paragraph": "1.制定个体化的治疗目标：(1)长期血糖控制目标：一般而言，以反映最近2~3个月血糖控制情况的HbA1c为主要目标，兼顾空腹和餐后血糖达标(具体可参照《中国成人2型糖尿病Hbh1c控制目标的专家共识》，表3)。(2)短期血糖控制目标：一般住院患者，降糖治疗以即时血糖达标为主要目标。一般推荐7.8~10mmol/L(140~180mg/d1)为宜。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.制定个体化的治疗目标：(1)长期血糖控制目标：一般而言，以反映最近2~3个月血糖控制情况的HbA1c为主要目标，兼顾空腹和餐后血糖达标(具体可参照《中国成人2型糖尿病Hbh1c控制目标的专家共识》，表3)。",
          "start_idx": 0,
          "end_idx": 105,
          "entities": [
            {
              "entity_id": "T75",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 20
            },
            {
              "entity_id": "T76",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 42
            },
            {
              "entity_id": "T77",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 52
            },
            {
              "entity_id": "T78",
              "entity": "空腹和餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 67
            },
            {
              "entity_id": "T79",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 69
            },
            {
              "entity_id": "T80",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 80,
              "end_idx": 85
            },
            {
              "entity_id": "T81",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 80,
              "end_idx": 82
            },
            {
              "entity_id": "T82",
              "entity": "Hbh1c",
              "entity_type": "Test_items",
              "start_idx": 85,
              "end_idx": 90
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R27",
              "head_entity_id": "T81",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R28",
              "head_entity_id": "T82",
              "tail_entity_id": "T80"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "(2)短期血糖控制目标：一般住院患者，降糖治疗以即时血糖达标为主要目标。",
          "start_idx": 105,
          "end_idx": 141,
          "entities": [
            {
              "entity_id": "T83",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 5,
              "end_idx": 7
            },
            {
              "entity_id": "T84",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T85",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 28,
              "end_idx": 30
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "一般推荐7.8~10mmol/L(140~180mg/d1)为宜。",
          "start_idx": 141,
          "end_idx": 174,
          "entities": [
            {
              "entity_id": "T86",
              "entity": "7.8~10mmol/L(140~180mg/d1)",
              "entity_type": "Test_Value",
              "start_idx": 4,
              "end_idx": 30
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "12",
      "paragraph": "2.各种治疗方案的特点：目前临床中常见的胰岛素治疗方案有1天1次或2次基础胰岛素联合口服药、1天2次预混胰岛素方案、基础+餐时胰岛素方案。各种方案适用于不同的临床情况(根据患者的治疗意愿、能力、生活方式和血糖状况做出选择)，具体详见表4。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.各种治疗方案的特点：目前临床中常见的胰岛素治疗方案有1天1次或2次基础胰岛素联合口服药、1天2次预混胰岛素方案、基础+餐时胰岛素方案。",
          "start_idx": 0,
          "end_idx": 69,
          "entities": [
            {
              "entity_id": "T87",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T88",
              "entity": "1天1次或2次",
              "entity_type": "Frequency",
              "start_idx": 28,
              "end_idx": 35
            },
            {
              "entity_id": "T89",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 40
            },
            {
              "entity_id": "T90",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 42,
              "end_idx": 44
            },
            {
              "entity_id": "T91",
              "entity": "1天2次",
              "entity_type": "Frequency",
              "start_idx": 46,
              "end_idx": 50
            },
            {
              "entity_id": "T92",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 55
            },
            {
              "entity_id": "T93",
              "entity": "基础+餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 66
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R29",
              "head_entity_id": "T88",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R30",
              "head_entity_id": "T91",
              "tail_entity_id": "T92"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R31",
              "head_entity_id": "T91",
              "tail_entity_id": "T93"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "各种方案适用于不同的临床情况(根据患者的治疗意愿、能力、生活方式和血糖状况做出选择)，具体详见表4。",
          "start_idx": 69,
          "end_idx": 119,
          "entities": [
            {
              "entity_id": "T94",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 35
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "13",
      "paragraph": "3.不同治疗方案的选择：目前尚无循证医学证据证实何种胰岛素起始治疗方案更优，各权威学术组织推荐的胰岛素启动治疗方案不尽相同。多数国家和地区[美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南]推荐起始使用基础胰岛素。若血糖控制不达标，可加用餐时胰岛素。美国临床内分泌医师协会(AACE)/美国内分泌学院(ACE)专家共识推荐基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素1日多次注射、餐时胰岛素加二甲双胍这4种胰岛素方案中任一种均可作为起始治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.不同治疗方案的选择：目前尚无循证医学证据证实何种胰岛素起始治疗方案更优，各权威学术组织推荐的胰岛素启动治疗方案不尽相同。多数国家和地区[美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南]推荐起始使用基础胰岛素。若血糖控制不达标，可加用餐时胰岛素。美国临床内分泌医师协会(AACE)/美国内分泌学院(ACE)专家共识推荐基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素1日多次注射、餐时胰岛素加二甲双胍这4种胰岛素方案中任一种均可作为起始治疗。",
          "start_idx": 0,
          "end_idx": 288,
          "entities": [
            {
              "entity_id": "T95",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 29
            },
            {
              "entity_id": "T96",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 51
            },
            {
              "entity_id": "T97",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 75
            },
            {
              "entity_id": "T98",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 88
            },
            {
              "entity_id": "T99",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 110
            },
            {
              "entity_id": "T100",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 143,
              "end_idx": 146
            },
            {
              "entity_id": "T101",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 169
            },
            {
              "entity_id": "T102",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 171,
              "end_idx": 173
            },
            {
              "entity_id": "T103",
              "entity": "控制不达标",
              "entity_type": "Test_Value",
              "start_idx": 173,
              "end_idx": 178
            },
            {
              "entity_id": "T104",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 187
            },
            {
              "entity_id": "T105",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 224,
              "end_idx": 229
            },
            {
              "entity_id": "T106",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 230,
              "end_idx": 235
            },
            {
              "entity_id": "T107",
              "entity": "基础-餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 236,
              "end_idx": 244
            },
            {
              "entity_id": "T108",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 245,
              "end_idx": 250
            },
            {
              "entity_id": "T109",
              "entity": "1日多次",
              "entity_type": "Frequency",
              "start_idx": 250,
              "end_idx": 254
            },
            {
              "entity_id": "T110",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 254,
              "end_idx": 256
            },
            {
              "entity_id": "T111",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 257,
              "end_idx": 262
            },
            {
              "entity_id": "T112",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 263,
              "end_idx": 267
            },
            {
              "entity_id": "T113",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 270,
              "end_idx": 273
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R32",
              "head_entity_id": "T109",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R33",
              "head_entity_id": "T110",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R34",
              "head_entity_id": "T109",
              "tail_entity_id": "T106"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R35",
              "head_entity_id": "T110",
              "tail_entity_id": "T106"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R36",
              "head_entity_id": "T109",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R37",
              "head_entity_id": "T110",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R38",
              "head_entity_id": "T109",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R39",
              "head_entity_id": "T110",
              "tail_entity_id": "T108"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "14",
      "paragraph": "总体而言，预混胰岛素治疗达标率更高，基础胰岛素治疗低血糖发生率相对较低。亚裔糖尿病患者中以餐后血糖增高更常见，餐后血糖在血糖控制中的作用尤为重要。中国2型糖尿病防治指南(2010年版)指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服药物联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素治疗(基础胰岛素加餐时胰岛素或每日3次预混胰岛素。图1)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "总体而言，预混胰岛素治疗达标率更高，基础胰岛素治疗低血糖发生率相对较低。亚裔糖尿病患者中以餐后血糖增高更常见，餐后血糖在血糖控制中的作用尤为重要。中国2型糖尿病防治指南(2010年版)指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服药物联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素治疗(基础胰岛素加餐时胰岛素或每日3次预混胰岛素。",
          "start_idx": 0,
          "end_idx": 198,
          "entities": [
            {
              "entity_id": "T114",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T115",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 23
            },
            {
              "entity_id": "T116",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 25,
              "end_idx": 28
            },
            {
              "entity_id": "T117",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 41
            },
            {
              "entity_id": "T118",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 49
            },
            {
              "entity_id": "T119",
              "entity": "增高",
              "entity_type": "Test_Value",
              "start_idx": 49,
              "end_idx": 51
            },
            {
              "entity_id": "T120",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 59
            },
            {
              "entity_id": "T121",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 62
            },
            {
              "entity_id": "T122",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 80
            },
            {
              "entity_id": "T123",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 75,
              "end_idx": 77
            },
            {
              "entity_id": "T124",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T125",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 104
            },
            {
              "entity_id": "T126",
              "entity": "每日1~2次",
              "entity_type": "Frequency",
              "start_idx": 105,
              "end_idx": 111
            },
            {
              "entity_id": "T127",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 116
            },
            {
              "entity_id": "T128",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 123
            },
            {
              "entity_id": "T129",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 136
            },
            {
              "entity_id": "T130",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 142
            },
            {
              "entity_id": "T131",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 143,
              "end_idx": 145
            },
            {
              "entity_id": "T132",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 153,
              "end_idx": 155
            },
            {
              "entity_id": "T133",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 155,
              "end_idx": 158
            },
            {
              "entity_id": "T134",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 170,
              "end_idx": 173
            },
            {
              "entity_id": "T135",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 176,
              "end_idx": 181
            },
            {
              "entity_id": "T136",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 187
            },
            {
              "entity_id": "T137",
              "entity": "每日3次",
              "entity_type": "Frequency",
              "start_idx": 188,
              "end_idx": 192
            },
            {
              "entity_id": "T138",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 192,
              "end_idx": 197
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R40",
              "head_entity_id": "T116",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R41",
              "head_entity_id": "T118",
              "tail_entity_id": "T117"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R42",
              "head_entity_id": "T123",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R43",
              "head_entity_id": "T125",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R44",
              "head_entity_id": "T127",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R45",
              "head_entity_id": "T128",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R46",
              "head_entity_id": "T124",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R47",
              "head_entity_id": "T126",
              "tail_entity_id": "T127"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R48",
              "head_entity_id": "T137",
              "tail_entity_id": "T138"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "图1)。",
          "start_idx": 198,
          "end_idx": 202,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "15",
      "paragraph": "三、不同类别胰岛素的选择",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、不同类别胰岛素的选择",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [
            {
              "entity_id": "T139",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "17",
      "paragraph": "药物经济学已经成为评价临床治疗方案的重要手段之一。在选择2型糖尿病治疗方案时，应综合考虑控制医疗费用、患者病情及其支付能力等多方面因素。作为发展中国家，我国医疗资源仍相对匮乏，且糖尿病患者人数众多且增长迅猛，在为2型糖尿病制定胰岛素治疗方案时需考虑以上诸多因素。人胰岛素经济、安全、有效，在2型糖尿病治疗中发挥重要的作用。正是基于成本和效益比基础上，《国家基本医疗保险、工伤保险和生育保险药品目录(2009年版)》亦对胰岛素的选择做出规定(表5)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "药物经济学已经成为评价临床治疗方案的重要手段之一。在选择2型糖尿病治疗方案时，应综合考虑控制医疗费用、患者病情及其支付能力等多方面因素。作为发展中国家，我国医疗资源仍相对匮乏，且糖尿病患者人数众多且增长迅猛，在为2型糖尿病制定胰岛素治疗方案时需考虑以上诸多因素。",
          "start_idx": 0,
          "end_idx": 131,
          "entities": [
            {
              "entity_id": "T140",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 33
            },
            {
              "entity_id": "T141",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 28,
              "end_idx": 30
            },
            {
              "entity_id": "T142",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 92
            },
            {
              "entity_id": "T143",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 111
            },
            {
              "entity_id": "T144",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 106,
              "end_idx": 108
            },
            {
              "entity_id": "T145",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 116
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R49",
              "head_entity_id": "T141",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R50",
              "head_entity_id": "T144",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R51",
              "head_entity_id": "T145",
              "tail_entity_id": "T143"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "人胰岛素经济、安全、有效，在2型糖尿病治疗中发挥重要的作用。",
          "start_idx": 131,
          "end_idx": 161,
          "entities": [
            {
              "entity_id": "T146",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19
            },
            {
              "entity_id": "T147",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 14,
              "end_idx": 16
            },
            {
              "entity_id": "T148",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R52",
              "head_entity_id": "T147",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T148",
              "tail_entity_id": "T146"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "正是基于成本和效益比基础上，《国家基本医疗保险、工伤保险和生育保险药品目录(2009年版)》亦对胰岛素的选择做出规定(表5)。",
          "start_idx": 161,
          "end_idx": 224,
          "entities": [
            {
              "entity_id": "T149",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 51
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "16",
      "paragraph": "目前用于临床的胰岛素包括动物胰岛素、人胰岛素和胰岛素类似物。由于潜在免疫原性等问题，动物胰岛素在大多数地区使用逐渐减少，人胰岛素和胰岛素类似物使用逐渐增多。人胰岛素与人体自身分泌的胰岛素结构完全相同，胰岛素类似物通过改变胰岛素结构而改变胰岛素药代动力学特性。短期研究表明，胰岛素类似物与人胰岛素相比，控制HbA1c的能力相似，但使用更方便，在减少低血糖发生的潜在危险方面胰岛素类似物优于人胰岛素，这一优势主要表现在1型糖尿病患者。目前尚缺乏胰岛素类似物对患者长期终点事件，如死亡率、糖尿病相关微血管和大血管并发症等方面的证据。多项meta分析及临床研究显示，在2型糖尿病患者中，胰岛素类似物在HbA1c达标率、胰岛素剂量、体重、日问低血糖、严重低血糖和不良反应方面与人胰岛素相当，长效胰岛素类似物对夜间低血糖的改善优于NPH。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前用于临床的胰岛素包括动物胰岛素、人胰岛素和胰岛素类似物。由于潜在免疫原性等问题，动物胰岛素在大多数地区使用逐渐减少，人胰岛素和胰岛素类似物使用逐渐增多。人胰岛素与人体自身分泌的胰岛素结构完全相同，胰岛素类似物通过改变胰岛素结构而改变胰岛素药代动力学特性。短期研究表明，胰岛素类似物与人胰岛素相比，控制HbA1c的能力相似，但使用更方便，在减少低血糖发生的潜在危险方面胰岛素类似物优于人胰岛素，这一优势主要表现在1型糖尿病患者。目前尚缺乏胰岛素类似物对患者长期终点事件，如死亡率、糖尿病相关微血管和大血管并发症等方面的证据。多项meta分析及临床研究显示，在2型糖尿病患者中，胰岛素类似物在HbA1c达标率、胰岛素剂量、体重、日问低血糖、严重低血糖和不良反应方面与人胰岛素相当，长效胰岛素类似物对夜间低血糖的改善优于NPH。",
          "start_idx": 0,
          "end_idx": 363,
          "entities": [
            {
              "entity_id": "T150",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T151",
              "entity": "动物胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17
            },
            {
              "entity_id": "T152",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T153",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 29
            },
            {
              "entity_id": "T154",
              "entity": "动物胰岛素",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 47
            },
            {
              "entity_id": "T155",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64
            },
            {
              "entity_id": "T156",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 71
            },
            {
              "entity_id": "T157",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82
            },
            {
              "entity_id": "T158",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 106
            },
            {
              "entity_id": "T159",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 121
            },
            {
              "entity_id": "T160",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 136,
              "end_idx": 142
            },
            {
              "entity_id": "T161",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 147
            },
            {
              "entity_id": "T162",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 152,
              "end_idx": 157
            },
            {
              "entity_id": "T163",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 173,
              "end_idx": 176
            },
            {
              "entity_id": "T164",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 185,
              "end_idx": 191
            },
            {
              "entity_id": "T165",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 193,
              "end_idx": 197
            },
            {
              "entity_id": "T166",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 207,
              "end_idx": 212
            },
            {
              "entity_id": "T167",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 207,
              "end_idx": 209
            },
            {
              "entity_id": "T168",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 220,
              "end_idx": 226
            },
            {
              "entity_id": "T169",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 241,
              "end_idx": 244
            },
            {
              "entity_id": "T170",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 246,
              "end_idx": 249
            },
            {
              "entity_id": "T171",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 250,
              "end_idx": 253
            },
            {
              "entity_id": "T172",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 280,
              "end_idx": 285
            },
            {
              "entity_id": "T173",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 280,
              "end_idx": 282
            },
            {
              "entity_id": "T174",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 289,
              "end_idx": 295
            },
            {
              "entity_id": "T175",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 296,
              "end_idx": 301
            },
            {
              "entity_id": "T176",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 305,
              "end_idx": 308
            },
            {
              "entity_id": "T177",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 316,
              "end_idx": 319
            },
            {
              "entity_id": "T178",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 320,
              "end_idx": 322
            },
            {
              "entity_id": "T179",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 322,
              "end_idx": 325
            },
            {
              "entity_id": "T180",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 333,
              "end_idx": 337
            },
            {
              "entity_id": "T181",
              "entity": "长效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 340,
              "end_idx": 348
            },
            {
              "entity_id": "T182",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 351,
              "end_idx": 354
            },
            {
              "entity_id": "T183",
              "entity": "NPH",
              "entity_type": "Drug",
              "start_idx": 359,
              "end_idx": 362
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R54",
              "head_entity_id": "T163",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R55",
              "head_entity_id": "T163",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R56",
              "head_entity_id": "T164",
              "tail_entity_id": "T166"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R57",
              "head_entity_id": "T165",
              "tail_entity_id": "T166"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R58",
              "head_entity_id": "T167",
              "tail_entity_id": "T166"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R59",
              "head_entity_id": "T168",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R60",
              "head_entity_id": "T170",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R61",
              "head_entity_id": "T171",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R62",
              "head_entity_id": "T173",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R63",
              "head_entity_id": "T174",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R64",
              "head_entity_id": "T180",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R65",
              "head_entity_id": "T181",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R66",
              "head_entity_id": "T183",
              "tail_entity_id": "T172"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R67",
              "head_entity_id": "T175",
              "tail_entity_id": "T172"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "18",
      "paragraph": "四、胰岛素应用中应注意的问题",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、胰岛素应用中应注意的问题",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T184",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 5
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "19",
      "paragraph": "1.在积极使用胰岛素的同时，应合理使用胰岛素，避免过度应用。对于肥胖(体重指数>28kg/m2)的患者，应在口服药充分治疗的基础上起始胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.在积极使用胰岛素的同时，应合理使用胰岛素，避免过度应用。对于肥胖(体重指数>28kg/m2)的患者，应在口服药充分治疗的基础上起始胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 73,
          "entities": [
            {
              "entity_id": "T185",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T186",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 22
            },
            {
              "entity_id": "T187",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 34
            },
            {
              "entity_id": "T188",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 54,
              "end_idx": 56
            },
            {
              "entity_id": "T189",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 70
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R68",
              "head_entity_id": "T189",
              "tail_entity_id": "T187"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "20",
      "paragraph": "2.合理的联合用药，避免药物不良反应的产生和叠加。单独使用胰岛素的主要不良反应是低血糖和体重增加。推荐采用胰岛素/口服药联合方案，以增加降糖疗效，同时减少低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量。α-葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，减少胰岛素使用剂量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或α糖苷酶抑制剂与胰岛素联用。促泌剂可发生低血糖和体重增加的不良反应，因此，除基础胰岛素外，不建议胰岛素和促泌剂联合使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.合理的联合用药，避免药物不良反应的产生和叠加。单独使用胰岛素的主要不良反应是低血糖和体重增加。推荐采用胰岛素/口服药联合方案，以增加降糖疗效，同时减少低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量。α-葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，减少胰岛素使用剂量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或α糖苷酶抑制剂与胰岛素联用。",
          "start_idx": 0,
          "end_idx": 210,
          "entities": [
            {
              "entity_id": "T190",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T191",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 40,
              "end_idx": 43
            },
            {
              "entity_id": "T192",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T193",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 56
            },
            {
              "entity_id": "T194",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 57,
              "end_idx": 59
            },
            {
              "entity_id": "T195",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 77,
              "end_idx": 80
            },
            {
              "entity_id": "T196",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 81,
              "end_idx": 85
            },
            {
              "entity_id": "T197",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 91,
              "end_idx": 95
            },
            {
              "entity_id": "T198",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 99
            },
            {
              "entity_id": "T199",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T200",
              "entity": "外源性胰岛素",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 117
            },
            {
              "entity_id": "T201",
              "entity": "α-葡萄糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 130
            },
            {
              "entity_id": "T202",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 134
            },
            {
              "entity_id": "T203",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 141,
              "end_idx": 143
            },
            {
              "entity_id": "T204",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 149,
              "end_idx": 152
            },
            {
              "entity_id": "T205",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 159,
              "end_idx": 163
            },
            {
              "entity_id": "T206",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 179,
              "end_idx": 184
            },
            {
              "entity_id": "T207",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 179,
              "end_idx": 181
            },
            {
              "entity_id": "T208",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 191,
              "end_idx": 195
            },
            {
              "entity_id": "T209",
              "entity": "α糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 196,
              "end_idx": 203
            },
            {
              "entity_id": "T210",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 204,
              "end_idx": 207
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R69",
              "head_entity_id": "T191",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R70",
              "head_entity_id": "T192",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R71",
              "head_entity_id": "T199",
              "tail_entity_id": "T197"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R72",
              "head_entity_id": "T199",
              "tail_entity_id": "T198"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R73",
              "head_entity_id": "T205",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R74",
              "head_entity_id": "T207",
              "tail_entity_id": "T206"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R75",
              "head_entity_id": "T208",
              "tail_entity_id": "T206"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R76",
              "head_entity_id": "T209",
              "tail_entity_id": "T206"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R77",
              "head_entity_id": "T210",
              "tail_entity_id": "T206"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "促泌剂可发生低血糖和体重增加的不良反应，因此，除基础胰岛素外，不建议胰岛素和促泌剂联合使用。",
          "start_idx": 210,
          "end_idx": 256,
          "entities": [
            {
              "entity_id": "T211",
              "entity": "促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T212",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 6,
              "end_idx": 9
            },
            {
              "entity_id": "T213",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T214",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T215",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 37
            },
            {
              "entity_id": "T216",
              "entity": "促泌剂",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 41
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R78",
              "head_entity_id": "T212",
              "tail_entity_id": "T211"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R79",
              "head_entity_id": "T213",
              "tail_entity_id": "T211"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "21",
      "paragraph": "3.对已合并心脑血管疾病或危险因素的2型糖尿病患者，或老年糖尿病患者，过于激进的降糖治疗策略可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低，在使用胰岛素时，应采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.对已合并心脑血管疾病或危险因素的2型糖尿病患者，或老年糖尿病患者，过于激进的降糖治疗策略可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低，在使用胰岛素时，应采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。",
          "start_idx": 0,
          "end_idx": 136,
          "entities": [
            {
              "entity_id": "T217",
              "entity": "心脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 12
            },
            {
              "entity_id": "T218",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T219",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23
            },
            {
              "entity_id": "T220",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20
            },
            {
              "entity_id": "T221",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T222",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 87
            },
            {
              "entity_id": "T223",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 93
            },
            {
              "entity_id": "T224",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 106
            },
            {
              "entity_id": "T225",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 129,
              "end_idx": 132
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T218",
              "tail_entity_id": "T217"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T220",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T224",
              "tail_entity_id": "T222"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R83",
              "head_entity_id": "T224",
              "tail_entity_id": "T223"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R84",
              "head_entity_id": "T225",
              "tail_entity_id": "T224"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "22",
      "paragraph": "4.肾功能不全时肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症即血液中的尿素氮达9mmol[/L(25mg/d1)以上、肌酐达178μmol/L以上时，应根据血糖的监测及时减少和调整胰岛素的用量，使血糖维持在适当的范围内。胰岛素应优先选择短效、速效剂型。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.肾功能不全时肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症即血液中的尿素氮达9mmol[/L(25mg/d1)以上、肌酐达178μmol/L以上时，应根据血糖的监测及时减少和调整胰岛素的用量，使血糖维持在适当的范围内。",
          "start_idx": 0,
          "end_idx": 133,
          "entities": [
            {
              "entity_id": "T226",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T227",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            },
            {
              "entity_id": "T228",
              "entity": "肾脏对胰岛素的降解明显减少",
              "entity_type": "Pathogenesis",
              "start_idx": 8,
              "end_idx": 21
            },
            {
              "entity_id": "T229",
              "entity": "胰岛素排出速率下降",
              "entity_type": "Pathogenesis",
              "start_idx": 24,
              "end_idx": 33
            },
            {
              "entity_id": "T230",
              "entity": "胰岛素可能在体内蓄积",
              "entity_type": "Pathogenesis",
              "start_idx": 34,
              "end_idx": 44
            },
            {
              "entity_id": "T231",
              "entity": "氮质血症",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T232",
              "entity": "尿素氮",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 61
            },
            {
              "entity_id": "T233",
              "entity": "肌酐",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 84
            },
            {
              "entity_id": "T234",
              "entity": "达178μmol/L以上",
              "entity_type": "Test_Value",
              "start_idx": 84,
              "end_idx": 96
            },
            {
              "entity_id": "T235",
              "entity": "达9mmol[/L(25mg/d1)以上",
              "entity_type": "Test_Value",
              "start_idx": 61,
              "end_idx": 81
            },
            {
              "entity_id": "T236",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 116
            },
            {
              "entity_id": "T237",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 121,
              "end_idx": 123
            },
            {
              "entity_id": "T239",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 103
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R85",
              "head_entity_id": "T227",
              "tail_entity_id": "T226"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R86",
              "head_entity_id": "T228",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R87",
              "head_entity_id": "T229",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R88",
              "head_entity_id": "T230",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R89",
              "head_entity_id": "T232",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R90",
              "head_entity_id": "T233",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R91",
              "head_entity_id": "T239",
              "tail_entity_id": "T231"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "胰岛素应优先选择短效、速效剂型。",
          "start_idx": 133,
          "end_idx": 149,
          "entities": [
            {
              "entity_id": "T238",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "23",
      "paragraph": "5.在治疗过程中，应加强患者教育，通过多学科的专业合作，提升患者的自我管理能力。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.在治疗过程中，应加强患者教育，通过多学科的专业合作，提升患者的自我管理能力。",
          "start_idx": 0,
          "end_idx": 40,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "24",
      "paragraph": "6.对于注射胰岛素的患者，必须进行自我血糖监测。监测的频率取决于治疗的目标和方式[具体可参考：中国血糖监测临床应用指南(2011年版)]。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.对于注射胰岛素的患者，必须进行自我血糖监测。监测的频率取决于治疗的目标和方式[具体可参考：中国血糖监测临床应用指南(2011年版)]。",
          "start_idx": 0,
          "end_idx": 69,
          "entities": [
            {
              "entity_id": "T240",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9
            },
            {
              "entity_id": "T241",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 4,
              "end_idx": 6
            },
            {
              "entity_id": "T242",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 51
            },
            {
              "entity_id": "T243",
              "entity": "自我血糖监测",
              "entity_type": "Test_items",
              "start_idx": 17,
              "end_idx": 23
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R92",
              "head_entity_id": "T241",
              "tail_entity_id": "T240"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "25",
      "paragraph": "基于以上，成人2型糖尿病胰岛素临床应用中国专家共识推荐如下：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "基于以上，成人2型糖尿病胰岛素临床应用中国专家共识推荐如下：",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T244",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 12
            },
            {
              "entity_id": "T245",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 7,
              "end_idx": 9
            },
            {
              "entity_id": "T246",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 15
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R93",
              "head_entity_id": "T245",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R94",
              "head_entity_id": "T246",
              "tail_entity_id": "T244"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "26",
      "paragraph": "合理把握胰岛素启动治疗时机。新诊断2型糖尿病患者HbA1c≥9.0%同时合并明显临床症状，或合并严重并发症，2种或2种以上口服降糖药次大剂量治疗3个月后仍不达标者(HbA1c≥7.0%)，应启动胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "合理把握胰岛素启动治疗时机。新诊断2型糖尿病患者HbA1c≥9.0%同时合并明显临床症状，或合并严重并发症，2种或2种以上口服降糖药次大剂量治疗3个月后仍不达标者(HbA1c≥7.0%)，应启动胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 103,
          "entities": [
            {
              "entity_id": "T247",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T248",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 22
            },
            {
              "entity_id": "T249",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19
            },
            {
              "entity_id": "T250",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T251",
              "entity": "≥9.0%",
              "entity_type": "Test_Value",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T252",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T253",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 87
            },
            {
              "entity_id": "T254",
              "entity": "≥7.0%",
              "entity_type": "Test_Value",
              "start_idx": 87,
              "end_idx": 92
            },
            {
              "entity_id": "T255",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 100
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R95",
              "head_entity_id": "T249",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R96",
              "head_entity_id": "T250",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R97",
              "head_entity_id": "T253",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R98",
              "head_entity_id": "T255",
              "tail_entity_id": "T248"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "27",
      "paragraph": "基础胰岛素或预混胰岛素均可作为胰岛素起始治疗方案。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "基础胰岛素或预混胰岛素均可作为胰岛素起始治疗方案。",
          "start_idx": 0,
          "end_idx": 25,
          "entities": [
            {
              "entity_id": "T256",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T257",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 11
            },
            {
              "entity_id": "T258",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "28",
      "paragraph": "应综合考虑患者病情、经济能力等各方面的因素，对血糖控制的风险与益处、成本与效益以及可行性进行科学评估，选择合理的胰岛素。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "应综合考虑患者病情、经济能力等各方面的因素，对血糖控制的风险与益处、成本与效益以及可行性进行科学评估，选择合理的胰岛素。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T259",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25
            },
            {
              "entity_id": "T260",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 59
            }
          ],
          "relations": []
        }
      ]
    }
  ]
}